The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity

The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity

Abstract Aims Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have been used to identify cancer patients at increased ca...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniela Di Lisi, Cristina Madaudo, Giulia Alagna, Marco Santoro, Ludovico Rossetto, Sergio Siragusa, Giuseppina Novo
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:ESC Heart Failure
Subjects:
Cardio‐oncology
Cardiovascular prevention
Chronic myeloid leukaemia
Nilotinib
Ponatinib
Cardiovascular toxicity
Online Access:https://doi.org/10.1002/ehf2.13897
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ehf2.13897

Similar Items